BCHE and amyotrophic lateral sclerosis: Multi-targeted drugs with MAO and cholinesterase (ChE) inhibition, metal chelating and antioxidant activity have been developed from rasagiline and selegiline for treatment of PD, AD, HD, and amyotrophic lateral sclerosis (ALS) [199,200,201].